Drugs / Olinvacimab
Trials 7
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT03722342 | Jan → Nov 2019 | glioblastoma | PharmAbcine | Unknown | No outcome recorded |
| Phase 1 | NCT03720431 | Jan 2019 → Mar 2020 | triple-negative breast carcinoma | PharmAbcine | Unknown | No outcome recorded |
| Phase 1 | NCT01660360 | Nov 2011 → Sep 2013 | metastatic malignant neoplasm | PharmAbcine | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04751955 | Jan 2022 → Oct 2023 | colorectal cancer | Korean Cancer Study Group | Withdrawn | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT04986852 | Sep 2021 → Dec 2024 | triple-negative breast carcinoma | PharmAbcine | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT03856099 | Nov 2019 → Jul 2022 | glioblastoma | PharmAbcine | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT03033524 | Feb 2016 → Jun 2017 | glioblastoma | PharmAbcine | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Olinvacimab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04751955 ↗ |
| Known as | Tanibirumab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01660360 ↗ |
| Known as | TTAC-0001 | “* Olinvacimab (TTAC-0001) 16 mg/kg on D1, D8 and D15” NCT04986852 ↗ |
| Modality | Monoclonal antibody | “a fully human monoclonal antibody to vascular endothelial growth factor receptor 2 (VEGFR2/KDR)” NCT01660360 ↗ |
| Route | Intravenous | “Tanibirumab will be administered intravenously to such patients over 60 minutes” NCT01660360 ↗ |
| Target | KDR | “a fully human monoclonal antibody to vascular endothelial growth factor receptor 2 (VEGFR2/KDR)” NCT01660360 ↗ |